Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 2,208 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blinded (placebo) Clear all
Completed Phase 3 Interventional Results available

A Study of Actonel for the Prevention of Bone Loss

NCT00452439
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Actonel (Risedronate), Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Oct 17, 2026, 1:08 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Metoclopramide in Upper Gastrointestinal Bleed

NCT05746377
View directory record Official record
Conditions
Upper GI Bleeding, Bleeds Gastric, Bleed Ulcer, Hemorrhage Gastric, Hemorrhage; Ulcer
Interventions
Metoclopramide 10mg, Saline
Drug
Lead sponsor
Mercy Health System
Network
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rockford, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adjunctive Treatment of Chronic Migraine Using an Oral Dental Device

NCT04871581
View directory record Official record
Conditions
Chronic Migraine, Headache
Interventions
NTI-tss, Placebo
Device
Lead sponsor
ChairsideSplint.com
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Solana Beach, California
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 17, 2026, 1:08 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

NCT05804045
View directory record Official record
Conditions
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath
Interventions
Pimicotinib(ABSK021), Placebo
Drug
Lead sponsor
Abbisko Therapeutics Co, Ltd
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
8
States / cities
Beverly Hills, California • Durham, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects

NCT07809919
View directory record Official record
Conditions
Visceral Leishmaniasis, Chagas Disease
Interventions
LXE408, Placebo, Iohexol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 3 Interventional Results available

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

NCT02419612
View directory record Official record
Conditions
Diabetes
Interventions
Saxagliptin, Dapagliflozin, Glimepiride, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
22
States / cities
Birmingham, Alabama • Chandler, Arizona • Tempe, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Oct 17, 2026, 1:08 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

NCT01760005
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, Matching Placebo (E2814)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
490 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics Study of NDX-1017

NCT03298672
View directory record Official record
Conditions
Alzheimer Disease
Interventions
NDX-1017, Placebo
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
18 Years to 85 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Not applicable Interventional Results available

Effect of Dietary Glycemic Index on Beta-cell Function

NCT01386645
View directory record Official record
Conditions
Impaired Glucose Tolerance, Oxidative Stress, Prediabetes, Impaired Fasting Glucose
Interventions
low glycemic index (LGI) diet, high glycemic index (HGI) diet plus placebo (PLAC), high glycemic index diet plus N-acetylcysteine
Other · Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression

NCT00200902
View directory record Official record
Conditions
Depression
Interventions
Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro), Placebo, Interpersonal Clinical Interaction (ICI)
Drug · Other · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 3 Interventional Results available

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

NCT02091375
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome
Interventions
GWP42003-P 20 mg/kg/day Dose, Placebo control
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
13
States / cities
Miami, Florida • Orlando, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A/H5N1in Adult - Aventis

NCT00115986
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H5N1 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
452 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
3
States / cities
Torrance, California • Baltimore, Maryland • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Calm 2: A Study of Health and Wellness Products on Feelings of Anxiety, Stress, and Health Outcomes

NCT05837910
View directory record Official record
Conditions
Anxiety, Stress
Interventions
Calm Active Study Product 1.1 Usage, Calm Active Study Product 1.2 Usage, Calm Active Study Product 1.3 Usage, Placebo Control Form 1, Placebo Control Form 2, Calm Active Study Product 2.1 Usage, Placebo Control Form 3, Calm Active Study Product 3.1 Usage, Placebo Control Form 4, Calm Active Study Product 4.1 Usage
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
3,853 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis

NCT02950805
View directory record Official record
Conditions
Pulmonary/Respiratory Diseases
Interventions
Placebo, AZD5634
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

Green Tea or Polyphenon E in Preventing Lung Cancer in Former Smokers With Chronic Obstructive Pulmonary Disease

NCT00363805
View directory record Official record
Conditions
Lung Cancer Prevention
Interventions
green tea, Polyphenon E, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Sherry Chow
Other
Eligibility
40 Years to 80 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 28, 2013 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Double Blinded Randomized Trial Between Lidocaine And Plain Gel For Urethral Straight Catheterization And The Q-Tip Test

NCT00883103
View directory record Official record
Conditions
Pain
Interventions
2% Lidocaine jelly, Plain aqueous gel
Drug
Lead sponsor
Baystate Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2011 · Synced Oct 17, 2026, 1:08 PM EDT
Withdrawn Phase 2 Interventional

A Study to Evaluate the Efficacy of Somatropin in the Treatment of Patellar Tendinopathy

NCT02597660
View directory record Official record
Conditions
Tendinopathy
Interventions
Somatropin, Bacteriostatic saline, Progressive exercise program, Patellar tendon biopsy
Drug · Other · Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 17, 2026, 1:08 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension

NCT00737594
View directory record Official record
Conditions
Portal Hypertension
Interventions
Placebo, Cobiprostone
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 17, 2026, 1:08 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Can Testosterone Accelerate Injury Recovery After Arthroscopic Rotator Cuff Repair

NCT04345666
View directory record Official record
Conditions
Rotator Cuff Tears
Interventions
Testosterone cypionate, Placebos
Drug
Lead sponsor
Orthopedic Institute, Sioux Falls, SD
Other
Eligibility
45 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 3 Interventional Results available

MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)

NCT03721016
View directory record Official record
Conditions
Glabellar Lines, Lateral Canthal Lines
Interventions
MT10109L, Placebo
Drug
Lead sponsor
Medy-Tox
Industry
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
9
States / cities
Glendale, Arizona • Newport Beach, California • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 17, 2026, 1:08 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

NCT06655155
View directory record Official record
Conditions
Systemic Sclerosis (SSc)
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Plantation, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 2 Interventional

Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer

NCT01138163
View directory record Official record
Conditions
Non-small-cell Lung Cancer
Interventions
Docetaxel plus bavituximab or placebo
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
24
States / cities
Chandler, Arizona • Campbell, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT03563716
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Atezolizumab, Tiragolumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
11
States / cities
Tempe, Arizona • Fort Myers, Florida • St. Petersburg, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)

NCT02091206
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome
Interventions
GWP42003-P 5 mg/kg/day Dose, Placebo control, GWP42003-P 10 mg/kg/day Dose, GWP42003-P 20 mg/kg/day Dose
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
4 Years to 10 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 17, 2026, 1:08 PM EDT